An email is perhaps the least glamorous object in pharmaceutical marketing. A doctor will scan it between patients. A brand team may spend three months getting it ready. Every claim has to stand on clinical evidence; every statement about a benefit must sit beside an honest account of risk. By the time the last person has signed off, the audience may have moved on. Solstice looked at that email and saw an entire production system hiding behind a send button.
- Solstice makes and checks digital campaigns for pharmaceutical brands, then helps deploy and measure them.
- It began publicly as an AI assistant for medical, legal and regulatory review; it now sells an agency service wrapped around its software.
- Its 2026 figures are company reported: under 48 hours to MLR submission, about ten days to market, and 1.2 review rounds per asset on average.
- The useful idea: give every new draft an approved evidence library before asking AI to write a word.
The bottleneck was the product
In February 2025, Solstice announced a $3.5 million seed round and introduced an AI assistant for the medical, legal and regulatory process known as MLR. Its first pair of tools had unusually plain names: Fact Check Assistant and Regulatory Assistant. One checked a proposed claim against papers, drug labels and trial material. The other looked for conflicts with regulatory and brand rules. The aim was to catch a bad line before a committee had to catch it.
That sounds narrow until you understand the job. A pharma marketer cannot simply decide that a sentence is catchy and publish it. The company must support the claim, present risk fairly and honor its own prior decisions. A campaign with dozens of variations can multiply those checks. Solstice said early users cut evaluation cycle times by 74%. That is a company figure, but the premise is easy to grasp: fixing a claim while it is still a draft costs less time than sending a flawed asset through another formal review.
The seed announcement also revealed the larger ambition. The founders, Aris Saxena and Yiwen Li, spoke of a full-stack solution, from content creation through distribution. A year later, the product description had grown to match the ambition. Solstice now calls itself an AI-native marketing agency. It pairs software with people who know creative work, medicine and the hazards of making a drug claim in public.
“Our customers used to run three review cycles per asset; now they run one or two at most.”Aris Saxena, co-founder and CEO, in the 2026 Series A announcement
The creative brief starts with the label
The workflow begins with a brand library: approved assets, reference material and clinical data. Solstice’s claims intelligence system, Aurora, extracts and verifies usable statements from labels, publications and previously approved materials. A marketer then submits a brief through a dashboard. The platform and its engagement team generate personalized assets, fact-check them, collect feedback and pass the work into regulatory review. Solstice says its system can submit into Veeva and pull review comments back for revision. After approval, the team activates the campaign and studies its performance.
This sequence is the company’s competitive argument. A traditional agency may excel at a campaign idea and hand it to a separate regulatory process. A review tool may flag problems but leave the creative team to start again. Solstice puts the people and the checks in one loop, with approved evidence available before production starts. That does not make a regulator vanish. It makes the review committee less likely to receive a preventable mistake.
There is a small but telling product detail in Solstice’s Fair Balance Score. Prescription drug advertising must present benefits and risks without misleading emphasis. The score assesses the area, visual saliency, font and contrast devoted to each. Solstice says it tested public promotional materials and used expert review to set a working threshold. A number cannot settle every judgment about an ad, but it can make the argument more specific than “the warning feels too quiet.”
People still have to care
Solstice’s website describes an engagement team that reviews the generated asset and responds to feedback. Its 2026 announcement says in-house specialists judge both compliance and taste. That second word matters. A perfectly referenced email can still be dull. A striking one can still be wrong. The service is for brand teams trying to reach healthcare professionals, patients and payers across launch, growth and mature brands. It addresses an operational problem those teams know well: the desire to tailor a message to a real audience collides with the time needed to approve every variation.
The company has offered named customer voices. Elaine Kang, a marketing director at SpringWorks Therapeutics, endorsed its early review product in 2025. Kristine Saffrin, a marketing director at Alexion Pharmaceuticals, said in 2026 that her team moved from draft to approval in days. Solstice also says it has worked with several top-20 pharmaceutical brands and agencies. Those statements describe adoption, though public detail about contract sizes and the number of active brands is limited.
Saxena and Li had built together before. As University of Pennsylvania graduates, they won a 2021 innovation prize for Mobility Health, an at-home care venture. That earlier company tackled the difficulty of connecting people with a provider; Solstice tackles a different gap between a therapy and the people who may need to hear about it. The shared instinct is visible, though the two businesses should not be confused. In each, waiting is treated as a design problem.
What the $21 million buys
The May 2026 Series A, led by Transformation Capital with Twelve Below and Virtue Ventures participating, took Solstice’s announced funding to about $25 million. The company said it would spend the new capital on sales, product development and customer-facing staff. The business model is business-to-business: pharma teams work with Solstice’s agency and platform. It does not publish a price list, so there is no public figure for what a campaign or a seat costs. Buyers have to request a demo and scope the service.
Its cost claim is about time and labor in the broader workflow. Solstice says customers produce almost three times more content per quarter than with a traditional agency approach, while average review rounds fell from 3.2 to 1.2. Those numbers come from the company, without a public breakdown of sample size or calculation method. They are best read as a description of what Solstice says its current customers have achieved, not a guarantee for every drug or brand.
The offer will be strongest where a brand already has usable approved material, a steady stream of digital assets to make and a review team willing to work with the new workflow. It is a harder proposition when evidence is unsettled, a claim has no approved precedent or the buyer cannot connect creative work to review and campaign data. An AI assistant can shorten a loop that exists. It cannot invent a clinical basis for a sentence that should never be written.
There is a lesson here for anyone building software around a slow process. Solstice started at the point of friction, the review. Then it moved upstream to the brief and downstream to campaign performance. Each step made the previous one more useful. The result is a company that sells something more concrete than “AI content”: a shorter trip from a documented claim to a message that can actually be sent. For the humble pharma email, that is quite an itinerary.